Quick answer
What is the structure of cagrilintide? It is a long-acting analog of the 37-residue hormone amylin with three engineered features: backbone substitutions that suppress aggregation, the intramolecular disulfide ring retained from amylin, and a C20 fatty-diacid side chain attached through a linker to a lysine to promote albumin binding. It is made by solid-phase peptide synthesis, selective on-resin lipid attachment, oxidative ring closure and reversed-phase HPLC purification. The product page lists a molecular formula of C194H308N54O61 and a 10 mg lyophilized vial for laboratory research use only.
Cagrilintide is easiest to understand as a design exercise. Start with a hormone that is biologically interesting but physically awkward, then change it step by step until it behaves like a usable laboratory reagent. This article follows those steps: the amylin scaffold, the substitutions that suppress aggregation, the disulfide ring, the lipid side chain, and the general chemistry used to make and purify a long acylated peptide. It is a structural companion to the cagrilintide research guide, which covers mechanism and handling, and it adds the synthesis and analytical detail that the guide only summarizes. The material is supplied for laboratory research use only; not for human consumption.
The starting point: human amylin
Amylin, also called islet amyloid polypeptide, is a 37-residue peptide hormone with an amidated C-terminus and a disulfide bond between cysteines at positions 2 and 7. It is stored with insulin in pancreatic beta-cell granules and released with it. It was first purified from amyloid-rich pancreas tissue in 1987 (Cooper et al.), and the same property that made it easy to find, a tendency to form fibrils, is the one that makes it hard to use. Human amylin aggregates in aqueous solution, and the aggregation behavior of the islet amyloid polypeptide family is reviewed in detail by Westermark and colleagues.
For a laboratory this creates two practical problems. A solution that is aggregating does not have a fixed concentration, so any assay run on it is difficult to interpret. And the native hormone is cleared quickly in biological systems, so a long incubation or an animal study needs either repeated additions or a more persistent analog. Cagrilintide was designed around both problems, as described in the medicinal chemistry paper by Kruse and colleagues.
Three engineered features
The molecule differs from the parent hormone in three ways that are easy to name and worth keeping separate when thinking about analytical work.
| Feature | What changes | Problem it addresses | What it means for the bench |
|---|---|---|---|
| --- | --- | --- | --- |
| Backbone substitutions | Selected residues in the aggregation-prone region are replaced | Fibril formation in solution | Solutions are more predictable, though not immune to self-association |
| Disulfide ring | The Cys2–Cys7 bridge of amylin is retained | Receptor recognition depends on the ring conformation | Reducing agents change the molecule; avoid them in buffers |
| Fatty-diacid side chain | A C20 diacid is attached through a linker to a lysine | Short persistence of the native hormone | Albumin binding, higher hydrophobicity, adsorption to plastic |
The molecular formula on the cagrilintide product page is C194H308N54O61. That formula includes the lipid and linker, which is why the molecule is so much larger than a typical research peptide. The figures on the page should be read together with the certificate of analysis where one has been published for the lot in hand; how to read a COA explains the fields.
Why lipidation, and why a diacid
Attaching a fatty acid to a peptide is one of the standard ways to prolong its persistence in biological systems. The lipid binds reversibly to serum albumin, a protein that is abundant, slow to turn over and too large to be filtered by the kidney, so the peptide spends part of its time bound and protected. Kurtzhals and colleagues characterized this principle for fatty-acid-acylated insulins in 1995, measuring how chain length and structure affect albumin affinity, and the approach was later applied to incretin analogs such as semaglutide (Lau et al., 2015; reviewed by Knudsen and Lau, 2019).
Cagrilintide uses a long-chain diacid, meaning a fatty acid with a carboxyl group at each end. One carboxyl forms the amide bond to the linker; the other remains free and is negatively charged at neutral pH. That free carboxyl is thought to contribute to albumin binding strength, and it also changes how the molecule behaves in chromatography and in solution. A neutral hydrocarbon chain would be more purely hydrophobic; a diacid is an amphiphile with a charged head, which is why lipidated peptides foam when shaken and cling to polypropylene surfaces.
For a laboratory the consequence is a set of habits rather than a theory: use low-binding plastics, avoid vigorous agitation, and keep volumes of dilute solutions small. The same chemistry explains why the cagrilintide purity testing guide stresses the container and the sample preparation.
How a long acylated peptide is made
The following is the general route used for peptides of this class, not a description of any particular manufacturer's process. Solid-phase peptide synthesis, introduced by Merrifield in 1963 and reviewed for modern use by Palomo (2014), assembles the chain on an insoluble resin one residue at a time. Each cycle removes a temporary protecting group from the growing N-terminus, couples the next protected amino acid, and washes away excess reagents. Side-chain groups stay protected until the end.
Placing the lipid
The lysine that will carry the lipid is introduced with a side-chain protecting group that can be removed independently of the others. After the backbone is complete, that single group is cleaved selectively, and the linker and the mono-protected fatty diacid are coupled to the exposed amine. Doing this on resin keeps the chemistry simple and the excess reagent easy to wash away.
Cleavage and ring closure
The finished peptide is then released from the resin with strong acid, which also removes the remaining side-chain protection. The two cysteines are initially free thiols. Oxidation under dilute conditions closes the disulfide ring; dilution matters because concentrated peptide favors intermolecular disulfides, which are dimers and larger species rather than the intended ring.
Purification
Crude product contains the target plus a family of related peptides: sequences missing a residue, sequences with an incompletely removed protecting group, species with the lipid in the wrong place or missing, oxidized variants, dimers and small amounts of deamidated forms. Reversed-phase HPLC separates these on the basis of hydrophobicity (Aguilar's chapter on the method is a standard reference), and the target peak is collected, pooled and freeze-dried. A review of the environmental and efficiency costs of this whole sequence is given by Isidro-Llobet and colleagues. A cake of lyophilized peptide is the end product; what is lyophilization describes that step.
What can be wrong with the finished material
The chemistry above defines the failure modes, and each one can be matched to an analytical readout.
| Possible impurity | How it arises | How it can be detected |
|---|---|---|
| --- | --- | --- |
| Deletion or truncated sequences | Incomplete coupling or deprotection on resin | Lower-mass peaks by mass spectrometry; early-eluting HPLC peaks |
| Peptide without lipid | Incomplete acylation | Large retention shift on reversed-phase HPLC; mass lower by the lipid-linker mass |
| Lipid at a second site | Loss of selectivity in side-chain protection | Same mass, different retention; needs fragmentation or peptide mapping |
| Dimers and oligomers | Intermolecular disulfide formation or aggregation | Size-exclusion chromatography; higher-mass signals |
| Open (reduced) ring | Incomplete oxidation or later reduction | Mass two units higher; shifted retention |
| Oxidized or deamidated forms | Handling and storage | Small mass shifts; closely eluting peaks |
An HPLC purity figure reports the area of the main peak relative to all detected peaks at one wavelength. It does not report net peptide content, because counterions, residual water and salts occupy mass without absorbing light, and it can miss impurities that co-elute with the main peak. This is the reason the page for the compound says that identity is reported on the certificate of analysis where published, and why HPLC versus mass spectrometry is worth reading before interpreting any single number. Understanding HPLC purity covers the chromatographic side.
Reading the structure alongside related compounds
Comparing cagrilintide with other acylated peptides in the same catalog clarifies what is specific to it. Semaglutide and tirzepatide are incretin analogs that also carry a fatty-acid side chain on a lysine, but they act at different receptors and are built on a different backbone. Cagrilintide shares their lipidation logic and differs in the scaffold it protects. The older amylin analog pramlintide has no lipid and no albumin binding, so it is cleared quickly; the differences are laid out in cagrilintide versus pramlintide. For the sequence conventions used when reading these structures, including D-amino acids and N-terminal modifications, see understanding amino acid sequences.
Implications for experimental design
Three practical points follow from the chemistry. First, the stock concentration is a calculated number, not a measured one, until it is checked: it equals the labelled mass divided by the volume, and net peptide content may be lower than the labelled mass. Where an assay is sensitive to concentration, quantify the stock by an orthogonal method such as amino acid analysis or quantitative HPLC against a reference. Second, because the ring and the lipid both carry function, any step that opens the ring or strips the lipid changes the compound under study; keep reducing agents, extreme pH and prolonged warm incubation out of the stock. Third, document lot number and storage history, since small variants such as the open-ring form accumulate with time in solution. The reconstitution calculator handles the volume arithmetic.
Summary
Cagrilintide is amylin with its weaknesses engineered out: substitutions against aggregation, a preserved disulfide ring for receptor recognition, and a fatty-diacid side chain for albumin binding. Each feature has a matching synthetic step and a matching analytical check, which makes the molecule a useful teaching example for lipidated peptides in general.
Frequently asked questions
What is cagrilintide made from?
It is built on the scaffold of amylin, a 37-residue pancreatic hormone, with amino-acid substitutions, a retained disulfide ring and a fatty-diacid side chain. It is a synthetic peptide produced chemically, not extracted from tissue.
Why does cagrilintide carry a fatty acid?
The lipid binds reversibly to serum albumin, which protects the peptide and extends its persistence in biological systems. The approach was characterized for acylated insulins and later reused for incretin and amylin analogs.
What is the molecular formula of cagrilintide?
The V8 product page lists C194H308N54O61. The formula includes the linker and the fatty diacid, so it describes the full acylated molecule rather than the bare peptide chain.
Is the disulfide bond in cagrilintide important?
Yes. The ring between the two cysteines is retained from native amylin and contributes to the conformation recognized by amylin-family receptors. Reducing agents such as DTT or TCEP break it and change the compound being studied.
How is a lipidated peptide synthesized?
In general, the chain is assembled on a resin, a selectively protected lysine is deprotected, the linker and fatty diacid are coupled, the peptide is cleaved from the resin, the disulfide ring is closed by dilute oxidation, and the product is purified by reversed-phase HPLC and freeze-dried.
Why is cagrilintide purity harder to judge than for a short peptide?
A long acylated peptide has more ways to be slightly wrong: missing lipid, lipid at another site, an open ring, dimers or truncations. Some of these co-elute on HPLC, so identity by mass spectrometry and a clear description of the method matter alongside the purity percentage.
Does an HPLC purity of 98% mean the vial contains 98% peptide by mass?
No. HPLC purity is the share of detected peak area belonging to the main peak. Water, counterions and salts add mass without absorbing at the detection wavelength, so net peptide content is a separate measurement.
Why does cagrilintide foam and stick to plastic?
The fatty-diacid side chain makes the molecule an amphiphile. It accumulates at air–water interfaces, which causes foam, and at hydrophobic surfaces, which causes loss to tube walls. Gentle swirling and low-binding plastics reduce both.
What forms does V8 supply cagrilintide in?
The product page lists a single 10 mg size, supplied as lyophilized powder in a sealed clear glass research vial, with purity stated as ≥98% by HPLC and storage at 2–8 °C, or −20 °C for long-term.
Related reading: Cagrilintide Primer: Names, Form and Lab Uses, Cagrilintide Rodent Studies: What Papers Report, How to Evaluate a Cagrilintide Supplier for Lab Work.
References
- Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565
- Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84(23):8628-8632. doi:10.1073/pnas.84.23.8628
- Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91(3):795-826. doi:10.1152/physrev.00042.2009
- Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J. 1995;312(3):725-731. doi:10.1042/bj3120725
- Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Palomo JM. Solid-phase peptide synthesis: an overview focused on the preparation of biologically relevant peptides. RSC Adv. 2014;4(62):32658-32672. doi:10.1039/C4RA02458C
- Isidro-Llobet A, Kenworthy MN, Mukherjee S, et al. Sustainability challenges in peptide synthesis and purification: from R&D to production. J Org Chem. 2019;84(8):4615-4628. doi:10.1021/acs.joc.8b03001
